Direct-To-Consumer Teledermatology’s Limitations May Be Addressed With Greater In-Person Care Synergy
January 2022
Studysummary This review discusses the potential conflicts of interest and quality concerns associated with direct-to-consumer teledermatology platforms and reports no new experimental results.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document discusses the limitations of direct-to-consumer (DTC) teledermatology platforms, highlighting concerns about financial conflicts of interest and the quality of care provided. While DTC platforms offer easy access and cost savings, they may not be suitable for complex cases and often depend on the sale of pharmaceutical products. In contrast, traditional in-person care can be more flexible and cost-effective, especially regarding prescription costs. The authors suggest that a synergistic model combining DTC and in-person care could improve access and quality, with triage systems determining the best care method for each patient. They encourage ongoing evaluation and improvement of DTC platforms by dermatologists and organizations.
